Press Releases

<< Back

CHF Solutions Initiates Strategic Collaboration with NI Medical on Management of Fluid Overloaded Patients

Oct 11, 2018

EDEN PRAIRIE, Minn., Oct. 11, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today that it has entered into a collaboration agreement with NI Medical to explore potential clinical synergies between the company’s Aquadex FlexFlow® System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume status and assist by informing on the management of a fluid overloaded patient.

The collaboration will initiate with a small patient evaluation when combining the Aquadex FlexFlow system with NI Medical’s, already 510k cleared, NICaS Hemodynamic Navigator in clinical practice. The two companies intend to evaluate the potential benefits of utilizing the cardiovascular, respiratory and fluid diagnostic parameters from NI Medical’s NICaS Hemodynamic Navigator to better understand fluid volume and hemodynamic parameters in patients during an ultrafiltration procedure using the Aquadex FlexFlow System. 

“We are dedicated to providing physicians with access to solutions that help them more effectively treat fluid overloaded patients”, said John Erb, chairman and CEO of CHF Solutions. “We believe that the collaboration with NI Medical allows us to assess the technology and provide a potential option to physicians to improve the treatment of patients with fluid overload when diuretics have failed.” 

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota, with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

About NI Medical

NI Medical is medical device company focused on commercializing the NICaS Hemodynamic Navigator. The NICaS Hemodynamic Navigator is a non-invasive hemodynamic monitor designed for continuous measuring of cardiac output, peripheral resistance, and body fluids. The system is intended to help improve treatment of congestive heart failure, hypertensive and dialysis patients. The system is designed to identify a patient’s hemodynamic state (vasoconstricted/ vasodilated) and volume status (hypovolemia/ hypervolemia). NI Medical is an Israeli corporation headquartered in Petach Tikva, Israel.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the potential synergies between Aquadex FlexFlow System and NI Medical’s non-invasive hemodynamic monitor, the clinical evaluation of the companies’ technologies and the potential options that the company may provide to physicians and patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

chf.jpg

Source: CHF Solutions, Inc.